CERo Therapeutics Holdings, Inc. (CERO)
NASDAQ: CERO · Real-Time Price · USD
7.52
-0.15 (-1.96%)
At close: Aug 29, 2025, 4:00 PM
7.50
-0.02 (-0.27%)
After-hours: Aug 29, 2025, 7:48 PM EDT

CERO Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
9.4310.733.952.840.43
Research & Development
6.755.473.72--
Other Operating Expenses
---0.060.14
Operating Expenses
17.0416.27.682.910.57
Operating Income
-17.04-16.2-7.68-2.91-0.57
Interest & Investment Income
0.070.030.142.84-
Other Non Operating Income (Expenses)
0.144.530.24--
EBT Excluding Unusual Items
-16.83-11.64-7.3-0.07-0.57
Gain (Loss) on Sale of Investments
-----0
Other Unusual Items
2.753.340.01--
Pretax Income
-14.08-8.3-7.29-0.07-0.57
Income Tax Expense
---0.6-0.03
Net Income
-14.08-8.3-7.29-0.67-0.54
Preferred Dividends & Other Adjustments
27.832.78--36.16
Net Income to Common
-41.91-11.09-7.29-0.67-36.71
Shares Outstanding (Basic)
10-0-
Shares Outstanding (Diluted)
10-0-
EPS (Basic)
-35.08-434.46--59.38-
EPS (Diluted)
-35.08-434.46--59.38-
EBITDA
-16.68-15.76-7.21--
D&A For EBITDA
0.360.440.46--
EBIT
-17.04-16.2-7.68-2.91-0.57
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q